ICYMI, the New Jersey Bioscience Center recently hosted a panel discussion exploring alternative funding sources for life sciences companies, and I found it incredibly insightful.
The discussion focused on securing funding from non-traditional sources and addressed these key questions:
* How were the next generation of drugs, diagnostics, and devices funded?
* What new models emerged that changed the funding paradigm?
* Was there a better way to fund early and emerging commercial biomedical research?
Thanks to the following for making this event happen:
NJEDA Princeton Innovation Center BioLabs